Solcoa Industries — Rare earth metals from halide-free chemistry
Solcoa Industries is a rare earth metals producer based in Alameda, CA. Founded in 2025, the company develops halide-free chemistries, engineers processes, and builds and operates its own modular reactors. Solcoa's innovative processes are designed to produce zero harmful emissions including toxic fluoride gases. The company currently produces samarium and neodymium-praseodymium (NdPr) metal and is constructing a new plant in Nevada.
Get it by email
Companies like Solcoa Industries go out every weekday morning. One-click unsubscribe.
- Round
- $75M
- Sectors
- Manufacturing, Biotechnology
- Logged
- September 25, 2026, in issue #39
- Website
- solcoaindustries.com
More in manufacturing and biotechnology
$128M Series A · generalflash.com
General Flash — Turns metal oxides into semiconductor-grade critical metals
General Flash has developed a new method for producing critical metals through an energy-efficient, emissions-free process. This technology allows for the direct conversion of metal oxides into high-purity, semiconductor-grade metals. The company aims to scale its production domestically to enhance American manufacturing and national security. With significant funding, General Flash is set to build one of the largest critical materials production plants in the world by 2027.
ManufacturingMiningPrecious metalsRavelinEnsemble VCLowercarbon Capital · +6 · +9
$1M · galy.co
GALY Co. — Cocoa and cotton grown from cells for brands
GALY grows cocoa and cotton from cells using biological processes, supplying brands with traceable, scalable ingredients without traditional farming.
Information technologyBiotechnology$1M+
$100M Series C · delixtherapeutics.com
Delix Therapeutics — Non-hallucinogenic psychedelic drugs for mental health
Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.
BiotechnologyData and analyticsHealthcareSV Health neurodegen fundStrategic Pharma$100M+ · +1 · +4